Navigation Links
Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
Date:6/16/2008

SAN DIEGO, June 16 /PRNewswire/ -- Victory Pharma, Inc., a specialty pharmaceutical company focused on pain and related areas of medicine, today announced the recent initiation of the first of two clinical studies for MGX006 antiemetic pivotal clinical program.

"Data from the Phase 2 studies confirming pivotal formulation selection and end-of-phase 2 discussions with the FDA regarding the registration study designs provides confidence that MGX006 will move rapidly through pivotal development," explained Dr. Shawn Scranton, Vice President of Scientific Operations. "Victory is pleased with the results to date and is confident that MGX006 will provide an important therapeutic alternative for patients suffering from emesis of various etiologies," continued Dr. Scranton.

"MGX006 represents a key milestone for Victory," stated Matthew Heck, President and CEO. "This novel approach to antiemetic therapy is the company's first internally developed pipeline product, demonstrating our commitment to developing solutions for unmet medical needs. We look forward to marketing MGX006 in the U.S. with our specialty sales force."

About MGX006

MGX006 utilizes a proprietary formulation applied to a previously approved antiemetic agent. The formulation was created utilizing patented technology through a partnership and has properties that make MGX006 ideally suited for the treatment of nausea and vomiting.

About Victory Pharma, Inc.

Victory Pharma, Inc. is a private San Diego based specialty pharmaceutical company focused on acquiring, marketing and developing proprietary pain and related products. Victory markets its existing pain products through its field sales force headquartered in Cary, NC, and is currently developing several products in pain and pain complementary markets. Further information regarding Victory is available at http://www.VictoryPharma.com.


'/>"/>
SOURCE Victory Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... PRINCETON, N.J., Oct. 9 Impliant, Inc., a ... fusion surgery, announced today that it conducted the ... the newest addition to its product portfolio. ... ) , The system is comprised of the ...
... ... HHC Nutrition Services will pay the United States $1.375 million to ... assistance under the guise of a sham durable medical equipment (DME) ... Corp., and its affiliate MediNet Corp. provided the kickbacks and assistance ...
Cached Medicine Technology:Impliant Conducts the First Two Implantations of Its New TOPS VersaLink Spinal System 2Impliant Conducts the First Two Implantations of Its New TOPS VersaLink Spinal System 3Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Kluger and co-workers from the Medical Oncology of Yale ... found that expression of high levels of TRAIL-R2 causes ... ,TRAIL receptors are cell surface receptors that ... expression was not associated with survival, high TRAIL-R2 expression ...
... in the summer months are quite difficult. Health problems due ... exhaustion and heat stroke. ,The recent issue of ... some tips to the elderly people that might make their ... to heading for the air conditioning, staying out of the ...
... suffer from the problem of excessive sweating even during ... relief from their condition. Researchers from Saint Louis University ... Botox (botulinum toxin type A) could be effective for ... long-term study of repeated treatment with Botox? (botulinum toxin ...
... no longer used to treat childhood asthma in Western// countries, ... routine cough in children with asthma. ,A study ... lack of good evidence for using Methylxanthines for children's cough ... author of the study Dr.Anne Chang, from Royal ...
... used to relieve anxiety symptoms, and valerian used for ... was reported in the first research study to be ... issue of the journal Medicine., ,The researchers Dr. ... California-San Francisco had performed an innovative Internet trial to ...
... one-day treatment with the anticancer drug carboplatin is as ... for a type of testicular cancer, according to results ... years standard care for stage 1 seminoma—a cancer of ... (hemi-castration) followed by three weeks radiotherapy. However, patients treated ...
Cached Medicine News:Health News:New Discovery to Increase Survival of Breast cancer Patients 2Health News:Elderly People Needs To Tackle The Heat Effectively 2Health News:Good News For Those Suffering From Excessive Sweating 2Health News:Good News For Those Suffering From Excessive Sweating 3Health News:Study Warns About The Use Of Popular Asthma Drug To Stop Children's Coughs 2Health News:Herbal Remedies For Insomnia And Anxiety May Be Ineffective 2
... The Trans-Blot Plus cell offers rapid ... 26.5 x 28 cm blotting area. ... gels, such as those used with ... versatile tank transfer system provides uniform ...
... vacuum regulator, base with vacuum stage, porous ... assorted window gaskets, lid, instructions. The ... transfers DNA or RNA from an agarose ... generally requires only 90 min for transfer, ...
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes ... allows for a very close positioning of the ... power source such as a battery charger, creates ... exceptionally rapid and exact electrophoretic transfer. ...
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes ... allows for a very close positioning of the ... power source such as a battery charger, creates ... exceptionally rapid and exact electrophoretic transfer. ...
Medicine Products: